H.C. Wainwright raised the firm’s price target on Personalis (PSNL) to $11 from $9 and keeps a Buy rating on the shares after Merck agreed to purchase $50M of Personalis’ common stock that translates to nearly 16.5% ownership interest. Merck’s investment not only helps to extend Personalis’ cash runway, but also serves as a testament to the growth potential of the company’s NeXT Personal ultrasensitive minimal residual disease testing business, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis receives $50M investment from Merck, extends pact with Moderna
- Cathie Wood’s ARK Investment bought 358.6K shares of Personalis today
- Personalis and Tempus AI extend commercial deal to biopharma industry
- Cathie Wood’s ARK Investment bought 266.8K shares of Personalis today
- Personalis price target lowered to $7 from $8 at Lake Street